Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Inhibition of METTL3 Results in a Cell-Intrinsic Interferon Response That Enhances Antitumor Immunity
Andrew A. Guirguis, Yaara Ofir-Rosenfeld, Kathy Knezevic, et al.
Cancer Discovery (2023) Vol. 13, Iss. 10, pp. 2228-2247
Closed Access | Times Cited: 54

Showing 1-25 of 54 citing articles:

Epigenetics-targeted drugs: current paradigms and future challenges
Wanlin Dai, Xinbo Qiao, Yuanyuan Fang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 28
The epitranscriptional factor PCIF1 orchestrates CD8+ T cell ferroptosis and activation to control antitumor immunity
Bolin Xiang, Meiling Zhang, Kai Li, et al.
Nature Immunology (2025) Vol. 26, Iss. 2, pp. 252-264
Closed Access | Times Cited: 4
HDAC2‐Mediated METTL3 Delactylation Promotes DNA Damage Repair and Chemotherapy Resistance in Triple‐Negative Breast Cancer
Xiaoniu He, Yuanpei Li, Jian Li, et al.
Advanced Science (2025)
Open Access | Times Cited: 3
Discovery, Optimization, and Preclinical Pharmacology of EP652, a METTL3 Inhibitor with Efficacy in Liquid and Solid Tumor Models
Guillaume Dutheuil, Killian Oukoloff, Julien Korac, et al.
Journal of Medicinal Chemistry (2025)
Closed Access | Times Cited: 2
Epigenetic Targets and Their Inhibitors in the Treatment of Idiopathic Pulmonary Fibrosis
Xiaohui Miao, Pan Liu, Yangyang Liu, et al.
European Journal of Medicinal Chemistry (2025) Vol. 289, pp. 117463-117463
Closed Access | Times Cited: 2
Functional Impacts of Epitranscriptomic m6A Modification on HIV-1 Infection
Stacia Phillips, Tarun Mishra, Siyu Huang, et al.
Viruses (2024) Vol. 16, Iss. 1, pp. 127-127
Open Access | Times Cited: 12
The impact of tRNA modifications on translation in cancer: identifying novel therapeutic avenues
Ana M. Añazco-Guenkova, Borja Miguel‐López, Óscar Monteagudo-García, et al.
NAR Cancer (2024) Vol. 6, Iss. 1
Open Access | Times Cited: 9
Exploring the role of ribosomal RNA modifications in cancer
Judith López, Sandra Blanco
Current Opinion in Genetics & Development (2024) Vol. 86, pp. 102204-102204
Open Access | Times Cited: 9
The combination of methionine adenosyltransferase 2A inhibitor and methyltransferase like 3 inhibitor promotes apoptosis of non-small cell lung cancer cells and produces synergistic anti-tumor activity
Yi-Fei Xuan, Shan Lu, Ying-Jie Ou, et al.
Biochemical and Biophysical Research Communications (2024) Vol. 716, pp. 150011-150011
Closed Access | Times Cited: 8
N6-methyladenosine modification—a key player in viral infection
Xiaoyue Zhang, Peng Qiu, Lujuan Wang
Cellular & Molecular Biology Letters (2023) Vol. 28, Iss. 1
Open Access | Times Cited: 16
RNA modifications in the progression of liver diseases: from fatty liver to cancer
Simiao Li‐Sauerwine, Wajahat Z. Mehal, Xinshou Ouyang
Science China Life Sciences (2024) Vol. 67, Iss. 10, pp. 2105-2119
Open Access | Times Cited: 5
m6A RNA methylation controls salivary gland epithelial cell function and has a protective role in Sjögren’s disease
Frederic Truffinet, Alejandro Arco-Hierves, Hosnia Shalabi, et al.
Annals of the Rheumatic Diseases (2024), pp. ard-226224
Closed Access | Times Cited: 5
Regulation of inflammatory diseases via the control of mRNA decay
Masanori Yoshinaga, Osamu Takeuchi
Inflammation and Regeneration (2024) Vol. 44, Iss. 1
Open Access | Times Cited: 4
Targeting RNA modifications with pharmacological agents: New frontiers in cancer therapy
Angel Guan, Justin Wong
Cancer Medicine (2024) Vol. 13, Iss. 7
Open Access | Times Cited: 4
Colorectal cancer-specific IFNβ delivery overcomes dysfunctional dsRNA-mediated type I interferon signaling to increase the abscopal effect of radiotherapy
Kevin Chih‐Yang Huang, Shu‐Fen Chiang, Hsin‐Yu Chang, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 5, pp. e008515-e008515
Open Access | Times Cited: 4
Clinical Perspectives in Epitranscriptomics
Eloy Santos-Pujol, Carlos Quero-Dotor, Manel Esteller
Current Opinion in Genetics & Development (2024) Vol. 87, pp. 102209-102209
Open Access | Times Cited: 4
Patent landscape of small molecule inhibitors of METTL3 (2020-present)
Zhixing Wu, Alexis R. Smith, Zhijian Qian, et al.
Expert Opinion on Therapeutic Patents (2024), pp. 1-16
Closed Access | Times Cited: 4
m5C methylation modification may be an accomplice in colorectal cancer escaping from anti-tumor effects of innate immunity-type I/III interferon
Yiqi Sun, Yunfei Liu, Lu Jiang, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access
The immunological landscape of CCL26High invasive oral squamous cell carcinoma
Lingyun Liu, Shuo Guan, Yuan Xue, et al.
Frontiers in Cell and Developmental Biology (2025) Vol. 13
Open Access
Epitranscriptomics in the Glioma Context: A Brief Overview
Pablo Santamarina‐Ojeda, Agustín F. Fernández, Mario F. Fraga
Cancers (2025) Vol. 17, Iss. 4, pp. 578-578
Open Access
The m6A revolution: transforming tumor immunity and enhancing immunotherapy outcomes
Tongguo Shi, Huan Zhang, Yueqiu Chen
Cell & Bioscience (2025) Vol. 15, Iss. 1
Open Access
RBM15-MKL1 fusion protein promotes leukemia via m6A methylation and WNT pathway activation
Madeline Y. Mayday, Giulia Biancon, Manyi Wei, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
Rethinking RNA Modifications: Therapeutic Strategies for Targeting Dysregulated RNA
Isobel E. Bowles, Esteban A. Orellana
Journal of Molecular Biology (2025), pp. 169046-169046
Closed Access
Recent Advances in Medicinal Chemistry Strategies for the Development of METTL3 Inhibitors
G. Li, Wei Chen, Dan Liu, et al.
European Journal of Medicinal Chemistry (2025), pp. 117560-117560
Closed Access
Switching from messenger RNAs to noncoding RNAs, METTL3 is a novel colorectal cancer diagnosis and treatment target
J Liao, Wen-Juan Ni, Peipei Wu, et al.
World Journal of Gastrointestinal Oncology (2025) Vol. 17, Iss. 5
Open Access
Page 1 - Next Page

Scroll to top